Evidence-based summary of human clinical trials for berberine, covering blood glucose regulation, lipid metabolism, and broader cardiometabolic health outcomes.

This page summarizes peer-reviewed human clinical trials investigating the effects of berberine on metabolic health outcomes.

Quick Answer

Berberine has been evaluated in numerous randomized controlled trials and meta-analyses for blood glucose, HbA1c, lipid parameters, and broader cardiometabolic outcomes. Across published studies, berberine is associated with improvements in fasting blood glucose, HbA1c, triglycerides, and LDL cholesterol, although effect sizes vary by population, formulation, dose, and study design. Head-to-head and adjunct-use studies suggest berberine may be a useful option for metabolic health support, but it should not be viewed as a substitute for individualized medical care.

The studies summarized below represent selected human clinical trials and reviews frequently cited in the literature.

Mechanism Overview

Berberine is an isoquinoline alkaloid found in plants like Berberis vulgaris, Coptis chinensis, and Hydrastis canadensis. Its metabolic effects are commonly linked to several pathways:

AMPK activation: Berberine is frequently described as activating AMP-activated protein kinase, a key regulator of glucose uptake, fatty acid oxidation, and cellular energy balance.
Insulin signaling: Some studies suggest improved insulin sensitivity and changes in insulin-receptor-related signaling.
Hepatic glucose output: Berberine has been investigated for effects on pathways involved in gluconeogenesis.
Lipid metabolism: Research commonly discusses LDL receptor activity and broader lipid-regulation pathways.
Inflammatory signaling: Preclinical and mechanistic work often notes activity involving NF-κB and cytokine signaling.

Bioavailability is limited, which is one reason many clinical studies use divided daily doses.

Human Clinical Trials Summary

Blood Glucose & HbA1c (Type 2 Diabetes)

Study	Design	Dose	Duration	Key Findings	PMID
Yin et al., 2008	RCT, n=116	500mg 3x/day	3 months	Berberine was associated with improvements in HbA1c and fasting blood glucose; results were discussed alongside metformin in the study.	18397984
Lan et al., 2015 (Meta-analysis)	14 RCTs, n=1,068	0.5–1.5g/day	8–24 weeks	Meta-analysis reported reductions in fasting blood glucose and HbA1c versus control conditions.	25498346
Dong et al., 2012	Review / meta-analysis	Variable	Variable	Review-level evidence supported improvements in glycemic markers, while also noting variability across trial quality and design.	22529876

Lipid Profile (Cholesterol & Triglycerides)

Study	Design	Dose	Duration	Key Findings	PMID
Kong et al., 2004	Clinical study	500mg 2x/day	3 months	Berberine was associated with reductions in total cholesterol, LDL cholesterol, and triglycerides.	15531914
Derosa et al., 2013	RCT, n=144	500mg 2x/day + silymarin	12 months	Combination use was associated with improvements in LDL cholesterol and insulin-related markers.	24066856

PCOS & Metabolic Syndrome

Study	Design	Dose	Duration	Key Findings	PMID
Wei et al., 2012	RCT, n=89	500mg 3x/day	3 months	Berberine showed metabolic improvements in women with PCOS, with results discussed relative to metformin.	22081094

Dosages Used in Studies

Blood Glucose / Diabetes

500mg 2–3x/day (1,000–1,500mg total)
Often taken with meals
Typical duration: 8–12 weeks minimum

Lipid Management

500mg 2x/day (1,000mg total)
Sometimes used in combination formulas in clinical settings

PCOS / Metabolic Support

Common clinical range: 400–500mg 2–3x/day
Longer study durations are often used for endocrine and metabolic outcomes

Practical Notes

Divided dosing is common because of berberine’s limited bioavailability
Taking with meals may improve tolerability for some users

Safety & Contraindications

Berberine is generally well tolerated in many clinical studies, but gastrointestinal side effects are fairly common.

Common side effects: Diarrhea, constipation, gas, and abdominal discomfort
Dose-related tolerability: GI side effects may increase at higher daily intakes
Drug interactions: Potential interactions are discussed with glucose-lowering medications and with drugs affected by CYP-related metabolism
Pregnancy / breastfeeding: Generally avoided unless specifically advised by a qualified clinician

Important: Because berberine may affect blood glucose, people using diabetes medications should speak with a healthcare professional before use.

Evidence Summary

Blood Glucose (Type 2 Diabetes): Strong evidence (Grade A−) — Multiple randomized trials and meta-analyses support improvements in fasting blood glucose and HbA1c, though results vary across populations and protocols.
Lipid Management: Strong evidence (Grade A−) — Multiple studies support reductions in LDL cholesterol and triglycerides.
PCOS: Moderate evidence (Grade B) — Early human studies suggest benefits for insulin sensitivity and some reproductive outcomes, but more replication is needed.
Weight Management: Preliminary to moderate evidence (Grade B−) — Any weight-related effects appear modest and may be secondary to metabolic improvements.
Mechanistic Support: Strong preclinical rationale — AMPK activation and lipid-regulation pathways are commonly proposed, but clinical outcomes remain the most important basis for interpretation.

References

Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717. PMID: 18397984
Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81. PMID: 25498346
Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351. PMID: 15531914
Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654. PMID: 22529876
Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99-105. PMID: 22081094
Derosa G, Bonaventura A, Bianchi L, et al. Effects of berberine on lipid profile in subjects with low cardiovascular risk. PMID: 24066856

Only selected human trials and reviews are included here. Additional citations can be added after PMID/title verification.

Last updated: March 2026. This page summarizes published peer-reviewed research and is not medical advice. Consult a healthcare provider before starting any supplement.

Berberine Clinical Studies